Matinas Biopharma Announces That University Of Minnesota Medical School Researchers Published Results From The Phase 2 EnACT Trial Evaluating Mat2203 For Cryptococcal Meningitis As A Major Article And Editor's Choice In Clinical Infectious Diseases
Portfolio Pulse from Benzinga Newsdesk
Matinas Biopharma announced that researchers from the University of Minnesota Medical School have published results from the Phase 2 EnACT trial evaluating Mat2203 for Cryptococcal Meningitis. The results were published as a major article and editor's choice in Clinical Infectious Diseases.
August 22, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of positive results from the Phase 2 EnACT trial evaluating Mat2203 could potentially boost investor confidence in Matinas Biopharma.
The publication of positive trial results is typically seen as a positive development for biopharma companies, as it indicates progress in the development of their products. This could potentially lead to increased investor confidence in the company, which could in turn positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100